MX344787B - Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara. - Google Patents

Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.

Info

Publication number
MX344787B
MX344787B MX2011014006A MX2011014006A MX344787B MX 344787 B MX344787 B MX 344787B MX 2011014006 A MX2011014006 A MX 2011014006A MX 2011014006 A MX2011014006 A MX 2011014006A MX 344787 B MX344787 B MX 344787B
Authority
MX
Mexico
Prior art keywords
skin disorders
related skin
berberine
red face
analogs
Prior art date
Application number
MX2011014006A
Other languages
English (en)
Other versions
MX2011014006A (es
Inventor
Chung Wen-Hung
Chang Tse-Wen
Hung Shuen-Iu
Original Assignee
Shuen- Lu Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shuen- Lu Huang filed Critical Shuen- Lu Huang
Publication of MX2011014006A publication Critical patent/MX2011014006A/es
Publication of MX344787B publication Critical patent/MX344787B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención describe formulaciones farmacéuticas tópicas de berberina y sus análogos biológicamente equivalentes, tales como palmatina y coptisina, para el tratamiento de rosácea y otros trastornos de la piel relacionados con enrojecimiento de la cara. Las formulaciones farmacéuticas tópicas de esta invención contienen berberina purificada como el ingrediente de fármaco activo primario a concentraciones mayores de 0.1%. La invención también describe métodos para tratar rosácea y otros trastornos de la piel relacionados con enrojecimiento de la cara, tales como dermatitis tipo rosácea inducida por esteroides, que comprende la administración de formulaciones farmacéuticas tópicas que contienen berberina o sus análogos biológicamente equivalentes, tales como palmatina.
MX2011014006A 2009-06-30 2010-06-30 Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara. MX344787B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22172509P 2009-06-30 2009-06-30
PCT/CN2010/000983 WO2011000218A1 (en) 2009-06-30 2010-06-30 Compositions containing berberine or analogs thereof for treating rosacea or red face related skin disorders

Publications (2)

Publication Number Publication Date
MX2011014006A MX2011014006A (es) 2012-06-12
MX344787B true MX344787B (es) 2017-01-05

Family

ID=43410481

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011014006A MX344787B (es) 2009-06-30 2010-06-30 Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.

Country Status (16)

Country Link
US (1) US9486402B2 (es)
EP (1) EP2448577B1 (es)
JP (2) JP6159084B2 (es)
KR (3) KR20170010442A (es)
CN (2) CN102481290A (es)
AU (1) AU2010268647B2 (es)
BR (1) BRPI1012128A2 (es)
CA (1) CA2766834C (es)
ES (1) ES2600909T3 (es)
HK (1) HK1224206A1 (es)
IL (1) IL217264A (es)
MX (1) MX344787B (es)
NZ (1) NZ597645A (es)
PL (1) PL2448577T3 (es)
RU (2) RU2533458C2 (es)
WO (1) WO2011000218A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201538156A (zh) * 2013-12-19 2015-10-16 Twi Biotechnology Inc 小蘗鹼配方及其用途
US20160263092A1 (en) 2013-12-19 2016-09-15 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
CA2990237A1 (en) * 2015-06-24 2016-12-29 Twi Biotechnology, Inc. Therapeutic uses of berberine formulations
EP3445330B1 (en) 2016-04-19 2022-07-06 The U.S.A. as represented by the Secretary, Department of Health and Human Services Use of gram negative species to treat atopic dermatitis
US10293005B2 (en) 2016-04-19 2019-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of gram negative species to treat atopic dermatitis
SG11201907443PA (en) * 2017-01-19 2019-09-27 Twi Biotechnology Inc Methods and pharmaceutical compositions for preventing or treating immunoinflammatory dermal disorders
EP3398448A1 (en) 2017-05-05 2018-11-07 Vall Garraf, S.L. Fattening additive for animal nutritional composition
JP2021506958A (ja) 2017-12-13 2021-02-22 オンクォリティ ファーマシューティカルズ チャイナ エルティーディーＯｎｑｕａｌｉｔｙ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｈｉｎａ Ｌｔｄ． Ｅｇｆｒ阻害に関連する疾患を予防又は治療する方法
JP7520366B2 (ja) 2018-04-16 2024-07-23 オンクオリティー ファーマシューティカルズ チャイナ リミテッド 腫瘍療法の副作用の予防または治療方法
EP3784260A4 (en) * 2018-04-18 2022-03-09 Forte Subsidiary, Inc. Compositions for the treatment of skin conditions
CN108329310A (zh) * 2018-05-07 2018-07-27 深圳市迪克曼科技开发有限公司 黄藤素的制备方法
SG11202011188SA (en) 2018-05-11 2020-12-30 Forte Subsidiary Inc Compositions for the treatment of skin conditions
CN110882246B (zh) * 2018-09-08 2022-12-23 西南大学 不同生物活性的黄连生物碱的提取方法及应用
JP2020045338A (ja) * 2018-09-12 2020-03-26 大正製薬株式会社 外用組成物
CN112955139B (zh) 2018-09-25 2025-04-18 庞塞迪利昂健康特定活动公司 用于制备α-酮戊二酸钙的方法
JP6535146B1 (ja) * 2019-03-08 2019-06-26 佐藤製薬株式会社 皮膚バリア機能改善剤
RU2697854C1 (ru) * 2019-05-14 2019-08-21 Федеральное государственное бюджетное образовательное учреждение высшего образования "Сибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ комбинированной наружной терапии эритематозно-папулезной розацеа
CN113440613A (zh) * 2020-03-26 2021-09-28 轶诺(浙江)药业有限公司 小檗碱类似物与jak抑制剂在胃肠道炎症性疾病治疗中的用途
CN116370469A (zh) * 2023-04-27 2023-07-04 常州大学 四氢小檗碱类化合物对trpv3的抑制应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6150920A (ja) * 1984-08-20 1986-03-13 Ichimaru Fuarukosu Kk 黄柏抽出エキス含有液の製造法
JPS63179812A (ja) * 1987-01-22 1988-07-23 Shiseido Co Ltd 皮膚外用剤
JP2609564B2 (ja) * 1991-05-31 1997-05-14 政夫 斎藤 アレルギー性皮膚炎用クリーム及びその製造方法
CN1085600A (zh) * 1993-07-07 1994-04-20 南宁市迪生新技术研究所 防治性病、传染病的杀菌保健香皂和浴液
CN1182788A (zh) * 1997-02-03 1998-05-27 熊光明 一种防治性病传染病的保健洗涤用品
US6482839B1 (en) * 1997-06-02 2002-11-19 Cellegy Pharmaceuticals, Inc. Pyridine-thiols for treatment of a follicular dermatosis
US6440465B1 (en) * 2000-05-01 2002-08-27 Bioderm, Inc. Topical composition for the treatment of psoriasis and related skin disorders
JP2001335485A (ja) * 2000-05-31 2001-12-04 Pola Chem Ind Inc メラノサイトのデンドライトの伸長抑制剤及びそれを含有する化粧料
KR20030082200A (ko) * 2002-04-17 2003-10-22 주식회사 엘지생활건강 베르베린을 함유하는 아토피성 피부염 예방 및 완화용조성물
US20040146539A1 (en) 2003-01-24 2004-07-29 Gupta Shyam K. Topical Nutraceutical Compositions with Selective Body Slimming and Tone Firming Antiaging Benefits
WO2004093876A2 (en) * 2003-04-03 2004-11-04 The Board Of Trustees Of The University Of Illinois Composition containing berberine or a derivative thereof and an antimicrobial agent or an antibiotic agent, and their use for treating oral pathogens and other disorders
US7205006B2 (en) * 2003-09-25 2007-04-17 Prime Pharmaceutical Corporation Mahonia aquifolium extract, extraction process and pharmaceutical composition containing the same
WO2005048968A1 (en) 2003-11-17 2005-06-02 Sederma Compositions containing mixtures of tetrapeptides and tripeptides
US20050158404A1 (en) 2003-11-18 2005-07-21 Goodless Dean R. Composition and method for treatment of acne
EP1591125A1 (de) * 2004-04-19 2005-11-02 Universitätsklinikum Freiburg Pharmazeutische Zusammensetzung enthaltend Extrakte aus Flechten und Johanniskraut
CA2612408A1 (en) 2005-06-15 2006-12-28 Apollo Pharmaceutical, Inc. Pharmaceutical composition comprising a mahonia aquifolium extract for the treatment of psoriasis
CN100441183C (zh) * 2005-08-29 2008-12-10 中国医学科学院皮肤病研究所 盐酸13-己基小檗碱和盐酸13-己基巴马汀制备治疗湿疹、皮炎和银屑病的药物用途
DE202010004750U1 (de) * 2010-04-09 2011-10-11 Biofrontera Bioscience Gmbh Pharmazeutische oder/und kosmetische Zusammensetzung zur Behandlung der Haut

Also Published As

Publication number Publication date
CA2766834C (en) 2017-04-25
CA2766834A1 (en) 2011-01-06
JP2017082019A (ja) 2017-05-18
KR20170116231A (ko) 2017-10-18
IL217264A0 (en) 2012-02-29
JP2012531448A (ja) 2012-12-10
RU2014136492A (ru) 2016-03-27
KR20120047240A (ko) 2012-05-11
MX2011014006A (es) 2012-06-12
CN105534978A (zh) 2016-05-04
KR101699572B1 (ko) 2017-01-24
ES2600909T3 (es) 2017-02-13
WO2011000218A1 (en) 2011-01-06
CN102481290A (zh) 2012-05-30
NZ597645A (en) 2014-03-28
HK1224206A1 (zh) 2017-08-18
EP2448577B1 (en) 2016-09-14
JP6159084B2 (ja) 2017-07-05
US20120165357A1 (en) 2012-06-28
RU2671492C2 (ru) 2018-11-01
BRPI1012128A2 (pt) 2016-03-29
KR20170010442A (ko) 2017-01-31
US9486402B2 (en) 2016-11-08
EP2448577A4 (en) 2012-12-26
PL2448577T3 (pl) 2017-02-28
IL217264A (en) 2017-01-31
RU2012102898A (ru) 2013-08-10
EP2448577A1 (en) 2012-05-09
AU2010268647B2 (en) 2015-01-15
AU2010268647A1 (en) 2012-02-09
RU2533458C2 (ru) 2014-11-20

Similar Documents

Publication Publication Date Title
MX344787B (es) Composiciones que contienen berberina o analogos de la misma para tratar rosacea o trastornos de la piel relacionados con enrojecimiento de la cara.
PH12020550341A1 (en) Niraparib formulations
MX2022006258A (es) Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina.
MX2012012225A (es) Profármacos de agentes tearapéuticos de liberación de óxido nítrico.
MY168791A (en) Carbamate compounds and of making and using same
MY143795A (en) Tetrahydropyridoindole derivatives
EA201300556A1 (ru) Аминоспиртзамещенные производные 2,3-дигидроимидазо[1,2-с] хиназолина, пригодные для лечения гиперпролиферативных нарушений и заболеваний, связанных с ангиогенезом
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
PH12012502404A1 (en) Dry powder formulation comprising an antimuscarinic drug
PH12020500543A1 (en) Nonracemic mixtures and uses thereof
BR112012019374A2 (pt) composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MX2009008084A (es) Derivados de 5,6,7,8-tetrahidropteridina como inhibidores de hsp90.
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
MX2011011459A (es) Formulacion de clavulanato para neuroproteccion y tratamiento de trastornos neurodegenerativos.
SG10201907291QA (en) Monomethylfumarate prodrug compositions
WO2010090494A3 (ko) 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도
MX2015017879A (es) Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
WO2014130691A3 (en) Pharmaceutical formulations of nitrite and uses thereof
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
MX379253B (es) Formulaciones de oximetazolina estabilizadas y sus usos.
MX2016008546A (es) Reduccion de queloides utilizando alantoina topica.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
CR20220453A (es) Composiciones de palmitato de vitamina a, procesos para su preparación, usos y métodos que las componen

Legal Events

Date Code Title Description
FG Grant or registration